Altimmune, Inc., a biopharmaceutical company, is facing a class action lawsuit following a significant setback in its IMPACT Phase 2b MASH trial. The lawsuit, filed on behalf of shareholders, alleges securities fraud that has led to substantial financial losses for investors between August 10, 2023, and June 25, 2025. The controversy erupted after Altimmune released a press statement on June 26, 2025, revealing that the trial of their drug Pemvidutide failed to achieve statistical significance in reducing fibrosis, a key endpoint. This unexpected outcome was attributed to a higher-than-anticipated placebo response, leaving investors and analysts questioning the company’s prior optimistic projections.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The market reacted swiftly to the news, causing Altimmune’s stock to plummet by 53.2% overnight, from $7.71 to $3.61 per share. This dramatic decline underscores the gravity of the situation for shareholders who had placed their trust in the company’s promising forecasts.
For those who have incurred losses during this period, there is an opportunity to seek recovery. Affected investors are encouraged to visit [this link](https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?wire=18) to understand their rights and explore the possibility of joining the class action. Participation comes with no cost or obligation.
Levi & Korsinsky LLP is dedicated to representing all plaintiffs seeking justice in this case. With over two decades of experience and a track record of securing substantial settlements for shareholders, Levi & Korsinsky stands as a formidable advocate for investors seeking justice.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171